Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG s
暂无分享,去创建一个
Sung-Bae Kim | J. Ahn | Yeon-Hee Park | Y. Im | S. Im | K. Jung | Jin-Hee Ahn | Ji-yeon Kim | J. Sohn | J. Kim | J. Ro | Kyung-Hun Lee | Tae-Yong Kim | I. Park | K. Lee | G. Kim | Se Hyun Kim | Seonwoo Kim | Jeehyoung Kim | Ji-Yeon Kim | ji-Yeon Kim | J. Ahn | Seonwoo Kim